|
1）Corey SJ, Minden MD, Barber DL, et al. Myelo-dysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer. 2007; 7: 118-29
|
|
|
|
2）Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011; 29: 504-15
|
|
|
|
|
3）Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyl-transferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-15
|
|
|
|
|
|
4）Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-33
|
|
|
|
|
|
5）Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelo-dysplastic syndromes. Leukemia. 2011; 25: 1153-8
|
|
|
|
|
|
6）Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360: 2289-301
|
|
|
|
|
|
7）Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010; 95: 1668-74
|
|
|
|
|
|
8）Yoshida K, Sanada M, Kato M, et al. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia. 2011; 25: 184-6
|
|
|
|
|
|
9）Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-66
|
|
|
|
|
|
10）Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145: 788-800
|
|
|
|
|
|
11）Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42: 722-6
|
|
|
|
|
|
12）Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyl-transferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010; 42: 665-7
|
|
|
|
|
|
13）Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478: 64-9
|
|
|
|
|
|
14）Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365: 1384-95
|
|
|
|
|
|
15）Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010; 11: 685-96
|
|
|
|
|
|
16）Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature. 2010; 464: 993-8
|
|
|
|
|
|
17）Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012; 44: 53-7
|
|
|
|
|
|
18）Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012; 26: 542-5
|
|
|
|
|
|
19）Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011; 118: 6239-46
|
|
|
|
|
|
20）Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012; 119: 3211-8
|
|
|
|
|
|
21）Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120: 3080-8
|
|
|
|
|
|
22）Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelo-dysplastic syndromes. Blood. 2012; 119: 3578-84
|
|
|
|
|
|
23）Cui R, Gale RP, Xu Z, et al. Clinical importance of SF3B1 mutations in Chinese with myelo-dysplastic syndromes with ring sideroblasts. Leuk Res. 2012; 36: 1428-33
|
|
|
|
|
|
24）Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia. 2012; 26: 1137-40
|
|
|
|
|
|
25）Jeromin S, Haferlach T, Grossmann V, et al. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associ-ated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2012; [Epub ahead of print]
|
|
|
|
|
|
26）Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia. 2012; 26: 1135-7
|
|
|
|
|
|
27）Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelo-dysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012; 119: 569-572
|
|
|
|
|
|
28）Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012; 120: 3173-86
|
|
|
|
|
|
29）Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012; 120: 3106-11
|
|
|
|
|
|
30）Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012; 119: 4480-5
|
|
|
|
|
|
31）Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelo-dysplastic syndromes. J Clin Oncol. 2012; 30: 3376-82
|
|
|
|
|
|
32）Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lympho-cytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011; 118: 6904-8
|
|
|
|
|
|
33）Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365: 2497-506
|
|
|
|
|
|
34）Damm F, Nguyen-Khac F, Fontenay M, et al. Spliceosome and other novel mutations in chronic lymphocytic leukemia, and myeloid malignancies. Leukemia. 2012; 26: 2027-31
|
|
|
|
|
|
35）Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lympho-cytic leukemia. Nat Genet. 2012; 44: 47-52
|
|
|
|
|
|
36）Rossi D, Rasi S, Spina V, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012; 158: 426-9
|
|
|
|
|
|
37）Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150: 1107-20
|
|
|
|
|
|
38）Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol. 2009; 10: 741-54
|
|
|
|
|
|
39）Tronchere H, Wang J, Fu XD. A protein related to splicing factor U2AF35 that interacts with U2AF65 and SR proteins in splicing of pre-mRNA. Nature. 1997; 388: 397-400
|
|
|
|
|
|
40）Wahl MC, Will CL, Luhrmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009; 136: 701-18
|
|
|
|
|
|
41）Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012; 119: 3203-10
|
|
|
|
|
|
42）Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell. 1994; 77: 829-39
|
|
|
|
|
|
43）Serrano M, Lee H, Chin L, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996; 85: 27-37
|
|
|
|
|